Anmeldung erfolgt in Kürze...
Details werden geladen...
ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer’s Disease | The Manila Times
Cambridge, Massachusetts, July 27, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will host a webinar on Tuesday, July 28, 2026, at 8:00 am ET, featuring Key Opinion Leaders (KOLs) Dr. Will Mantyh, Associate Professor with Tenure, University of Minnesota Medical School and Dr. Michael Weiner, Professor Emeritus, University of California, San Francisco. They will join company leadership to discuss the Company's six-month blinded interim data from the PRECISE-AD Phase 1b trial evaluating PMN310 in patients with early Alzheimer's disease (AD). The analysis will focus on blinded aggregate safety data and overall trends in select biomarkers across study participants.
Ähnliche Seiten
ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial | The Manila Times
https://www.manilatimes.net/2026/07/28/tmt-newswire/globenewswire/promis-neurosciences-reports-positive-blinded-six-month-interim-safety-and-biomarker-data-for-pmn310-in-the-precise-ad-phase-1b-alzheimers-disease-trial/2392812
Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026 | The Manila Times
https://www.manilatimes.net/2026/06/03/tmt-newswire/globenewswire/tenaya-therapeutics-to-announce-new-interim-data-from-mypeak-1-phase-1b2-trial-of-tn-201-for-adults-with-mybpc3-associated-hcm-on-wednesday-june-3-2026/2357329Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome | The Manila Times
https://www.manilatimes.net/2026/06/13/tmt-newswire/globenewswire/rhythm-pharmaceuticals-to-announceinterim-six-month-phase-2-results-evaluating-setmelanotide-in-patients-with-prader-willi-syndrome/2364703Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 | The Manila Times
https://www.manilatimes.net/2026/06/13/tmt-newswire/globenewswire/rhythm-pharmaceuticals-presents-positive-interim-six-month-data-from-phase-2-trial-of-setmelanotide-in-patients-with-prader-willi-syndrome-pws-at-endo-2026/2364858Vanqua Bio to Present Positive Biomarker Data from Ongoing Phase 1b Study at Upcoming Medical Conferences | The Manila Times
https://www.manilatimes.net/2026/05/19/tmt-newswire/globenewswire/vanqua-bio-to-present-positive-biomarker-data-from-ongoing-phase-1b-study-at-upcoming-medical-conferences/2347027